Literature DB >> 24403584

The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.

Yoshiko Usami1, Sergei Popov, Heinrich G Göttlinger.   

Abstract

UNLABELLED: Human immunodeficiency virus type 1 (HIV-1) Nef enhances the infectivity of progeny virions. However, Nef is dispensable for the production of HIV-1 virions of optimal infectivity if the producer cells are superinfected with certain gammaretroviruses. In the case of the ecotropic Moloney murine leukemia virus (M-MLV), the Nef-like effect is mediated by the glycosylated Gag (glycoGag) protein. We now show that the N-terminal intracellular domain of the type II transmembrane protein glycoGag is responsible for its effect on HIV-1 infectivity. In the context of a fully active minimal M-MLV glycoGag construct, truncations of the cytoplasmic domain led to a near total loss of activity. Furthermore, the cytoplasmic domain of M-MLV glycoGag was fully sufficient to transfer the activity to an unrelated type II transmembrane protein. Although the intracellular region of glycoGag is relatively poorly conserved even among ecotropic and xenotropic MLVs, it was also fully sufficient for the rescue of nef-deficient HIV-1 when derived from a xenotropic virus. A mutagenic analysis showed that only a core region of the intracellular domain that exhibits at least some conservation between murine and feline leukemia viruses is crucial for activity. In particular, a conserved YXXL motif in the center of this core region was critical. In addition, expression of the μ2 subunit of the AP-2 adaptor complex in virus producer cells was essential for activity. We conclude that the ability to enhance HIV-1 infectivity is a conserved property of the MLV glycoGag cytoplasmic domain and involves AP-2-mediated endocytosis. IMPORTANCE: The Nef protein of HIV-1 and the entirely unrelated glycosylated Gag (glycoGag) protein of a murine leukemia virus (MLV) similarly enhance the infectiousness of HIV-1 particles by an unknown mechanism. MLV glycoGag is an alternative version of the structural viral Gag protein with an extra upstream region that provides a cytosolic domain and a plasma membrane anchor. We now show for the first time that the cytosolic domain of MLV glycoGag contains all the information needed to enhance HIV-1 infectivity and that this function of the cytosolic domain is conserved despite limited sequence conservation. Within the cytosolic domain, a motif that resembles a cellular sorting signal is critical for activity. Furthermore, the enhancement of HIV-1 infectivity depends on an endocytic cellular protein that is known to interact with such sorting signals. Together, our findings implicate the endocytic machinery in the enhancement of HIV-1 infectivity by MLV glycoGag.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403584      PMCID: PMC3957955          DOI: 10.1128/JVI.01933-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  89 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

3.  Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo.

Authors:  R Fujisawa; F J McAtee; J H Zirbel; J L Portis
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

6.  Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease.

Authors:  A A Bukovsky; T Dorfman; A Weimann; H G Göttlinger
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

9.  Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells.

Authors:  Claudia Muratori; Lucas E Cavallin; Kirsten Krätzel; Antonella Tinari; Angelo De Milito; Stefano Fais; Paola D'Aloja; Maurizio Federico; Vincenzo Vullo; Alla Fomina; Enrique A Mesri; Fabiana Superti; Andreas S Baur
Journal:  Cell Host Microbe       Date:  2009-09-17       Impact factor: 21.023

10.  Interaction of tyrosine-based sorting signals with clathrin-associated proteins.

Authors:  H Ohno; J Stewart; M C Fournier; H Bosshart; I Rhee; S Miyatake; T Saito; A Gallusser; T Kirchhausen; J S Bonifacino
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

View more
  23 in total

1.  Phosphoserine acidic cluster motifs bind distinct basic regions on the μ subunits of clathrin adaptor protein complexes.

Authors:  Rajendra Singh; Charlotte Stoneham; Christopher Lim; Xiaofei Jia; Javier Guenaga; Richard Wyatt; Joel O Wertheim; Yong Xiong; John Guatelli
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

2.  The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.

Authors:  Birthe Trautz; Virginia Pierini; Rebecka Wombacher; Bettina Stolp; Amanda J Chase; Massimo Pizzato; Oliver T Fackler
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

3.  Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Cindy Lam; María Carla Rosales Gerpe; Joanne Eileen McBane; Marc-André Langlois
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

4.  S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

Authors:  Ajit Chande; Emilia Cristiana Cuccurullo; Annachiara Rosa; Serena Ziglio; Susan Carpenter; Massimo Pizzato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-01       Impact factor: 11.205

5.  Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.

Authors:  Sunan Li; Iqbal Ahmad; Jing Shi; Bin Wang; Changqing Yu; Lixin Zhang; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

6.  A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.

Authors:  Charlotte A Stoneham; Peter W Ramirez; Rajendra Singh; Marissa Suarez; Andrew Debray; Christopher Lim; Xiaofei Jia; Yong Xiong; John Guatelli
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

7.  Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction.

Authors:  Xianfeng Zhang; Tao Zhou; Jie Yang; Yumei Lin; Jing Shi; Xihe Zhang; Dylan A Frabutt; Xiangwei Zeng; Sunan Li; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

8.  Selective Disruption of SERINC5 Antagonism by Nef Impairs SIV Replication in Primary CD4+ T Cells.

Authors:  Sanath Kumar Janaka; Alexandra V Palumbo; Aidin Tavakoli-Tameh; David T Evans
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

Review 9.  HIV-1 restriction by SERINC5.

Authors:  Lucía Cano-Ortiz; Tom Luedde; Carsten Münk
Journal:  Med Microbiol Immunol       Date:  2022-03-25       Impact factor: 3.402

10.  HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.

Authors:  Annachiara Rosa; Ajit Chande; Serena Ziglio; Veronica De Sanctis; Roberto Bertorelli; Shih Lin Goh; Sean M McCauley; Anetta Nowosielska; Stylianos E Antonarakis; Jeremy Luban; Federico Andrea Santoni; Massimo Pizzato
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.